CN116199698A - Functionalized D-glucal compound and preparation method thereof - Google Patents
Functionalized D-glucal compound and preparation method thereof Download PDFInfo
- Publication number
- CN116199698A CN116199698A CN202310246203.8A CN202310246203A CN116199698A CN 116199698 A CN116199698 A CN 116199698A CN 202310246203 A CN202310246203 A CN 202310246203A CN 116199698 A CN116199698 A CN 116199698A
- Authority
- CN
- China
- Prior art keywords
- glucal
- group
- vii
- acetone
- functionalized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 D-glucal compound Chemical class 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000003342 alkenyl group Chemical group 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 7
- 150000001540 azides Chemical class 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 abstract description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 5
- 125000000524 functional group Chemical group 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 2
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 abstract 1
- 150000002303 glucose derivatives Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- YVECGMZCTULTIS-PBXRRBTRSA-N glucal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1O YVECGMZCTULTIS-PBXRRBTRSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 108010058641 papulacandins Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YWJXCIXBAKGUKZ-HJJNZUOJSA-N Bergenin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]2C3=C(O)C(OC)=C(O)C=C3C(=O)O[C@@H]21 YWJXCIXBAKGUKZ-HJJNZUOJSA-N 0.000 description 1
- XULPLJSODQQHPH-UHFFFAOYSA-N Bergenin Natural products OCC1OC2C(OC(=O)c3cc(O)c(CO)c(O)c23)C(O)C1O XULPLJSODQQHPH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229930186782 Papulacandin Natural products 0.000 description 1
- XKSZJTQIZHUMGA-UHFFFAOYSA-N Papulacandin D Natural products OC1C(OC(=O)C=CC=CCC(O)C(C)=CC=CCCC(C)CC)C(O)C(CO)OC11C2=C(O)C=C(O)C=C2CO1 XKSZJTQIZHUMGA-UHFFFAOYSA-N 0.000 description 1
- FIFAQBUMNRZWOQ-UHFFFAOYSA-N Restricticin Natural products CCCC=CC=CC=C(C)C1OCC(C)C(OC)C1OC(=O)CN FIFAQBUMNRZWOQ-UHFFFAOYSA-N 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- FIFAQBUMNRZWOQ-YIXVSHAOSA-N [(2s,3s,4r,5r)-2-[(2e,4e,6e)-deca-2,4,6-trien-2-yl]-4-methoxy-5-methyloxan-3-yl] 2-aminoacetate Chemical compound CCC\C=C\C=C\C=C(/C)[C@@H]1OC[C@@H](C)[C@@H](OC)[C@@H]1OC(=O)CN FIFAQBUMNRZWOQ-YIXVSHAOSA-N 0.000 description 1
- XKSZJTQIZHUMGA-KDCKXVQZSA-N [(3'r,4's,5'r,6'r)-3',4,5',6-tetrahydroxy-6'-(hydroxymethyl)spiro[1h-2-benzofuran-3,2'-oxane]-4'-yl] (2e,4e,8e,10e)-7-hydroxy-8,14-dimethylhexadeca-2,4,8,10-tetraenoate Chemical compound O[C@@H]1[C@@H](OC(=O)/C=C/C=C/CC(O)C(/C)=C/C=C/CCC(C)CC)[C@H](O)[C@@H](CO)OC11C2=C(O)C=C(O)C=C2CO1 XKSZJTQIZHUMGA-KDCKXVQZSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- XKSZJTQIZHUMGA-HPZFVNCBSA-N papulacandin D Chemical compound O[C@@H]1[C@@H](OC(=O)/C=C/C=C/C[C@H](O)C(/C)=C/C=C/CC[C@@H](C)CC)[C@H](O)[C@@H](CO)O[C@@]11C2=C(O)C=C(O)C=C2CO1 XKSZJTQIZHUMGA-HPZFVNCBSA-N 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
技术领域Technical Field
本发明属于精细化工领域和糖化学领域,涉及手性含糖中间体的利用和转化,特别地公开了一种新型的功能化D-葡萄烯糖化合物及其制备方法。The invention belongs to the fields of fine chemical industry and sugar chemistry, relates to the utilization and conversion of chiral sugar-containing intermediates, and particularly discloses a novel functionalized D-glucal compound and a preparation method thereof.
背景技术Background Art
D-葡萄烯糖(I)是一种非常重要的糖类衍生物,可以方便地从葡萄糖或甘露糖制备而来。D-葡萄烯糖继承了天然糖D-葡萄糖的手性,其衍生物广泛地应用于有机合成中,是方便的六碳手性砌块。比较常用且重要的D-葡萄烯糖衍生物包括II、III、IV、V和VI中的任一种,具体如下:D-glucal (I) is a very important sugar derivative that can be easily prepared from glucose or mannose. D-glucal inherits the chirality of natural sugar D-glucose, and its derivatives are widely used in organic synthesis as convenient six-carbon chiral building blocks. The more commonly used and important D-glucal derivatives include any of II, III, IV, V and VI, as follows:
通过这些衍生物可以制备很多手性药物分子。比如以其三乙酰衍生物II为起始原料和手性源,可以制备Restricticin、SGLT-2inhibitor、Bergenin、Papulacandin D、Tricyclic flavonoid和Papulacandins A等。另外适当保护的烯糖还是方便的糖苷化给体;同时围绕着葡萄烯糖衍生物的环内烯醚官能团,许多有趣有用的反应被开发出来,大量结构新颖的手性化合物被制备出来。充分说明了D-葡萄烯糖及其衍生物在有机合成和药物化学等领域的重要性和高价值。Many chiral drug molecules can be prepared through these derivatives. For example, using its triacetyl derivative II as the starting material and chiral source, Restricticin, SGLT-2 inhibitor, Bergenin, Papulacandin D, Tricyclic flavonoid and Papulacandins A can be prepared. In addition, properly protected alkenyls are convenient glycosylation donors; at the same time, many interesting and useful reactions have been developed around the intracyclic alkenyl ether functional groups of glucal derivatives, and a large number of chiral compounds with novel structures have been prepared. This fully demonstrates the importance and high value of D-glucal and its derivatives in organic synthesis and medicinal chemistry.
发明内容Summary of the invention
本发明的目的在于提供一种新型的功能化D-葡萄烯糖化合物及其制备方法。在本发明中公开的功能化D-葡萄烯糖化合物制备方法的创新性在于在3-位羟基上安装了六种不同的官能基团,这些基团具有与烯糖环内烯醚反应,生成新结构衍生物。The purpose of the present invention is to provide a novel functionalized D-glucal compound and a preparation method thereof. The novelty of the preparation method of the functionalized D-glucal compound disclosed in the present invention is that six different functional groups are installed on the 3-hydroxyl group, and these groups have the ability to react with the enol ether in the glucal ring to generate new structural derivatives.
一种功能化D-葡萄烯糖化合物,具有通式结构VII,根据其功能取代基FG的种类分别用如下结构式VII-a、VII-b、VII-c、VII-d、VII-e和VII-f表示:A functionalized D-glucal compound has a general structure VII, and is represented by the following structural formulas VII-a, VII-b, VII-c, VII-d, VII-e and VII-f respectively according to the type of its functional substituent FG:
优选地,其中一种为3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖(VII-a),其结构通式为:Preferably, one of them is 3-O-acryloyl-4,6-O-acetone-D-glucal (VII-a), and its general structural formula is:
其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种。The R group is selected from any one of -H, alkyl, alkenyl, alkynyl and aryl.
优选地,其中一种为3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其结构通式为:Preferably, one of them is 3-O-propenyl ester-4,6-O-acetone-D-glucal (VII-b), and its general structural formula is:
其中,R基选自烷基、苄基、烯丙基中的任一种。The R group is selected from any one of an alkyl group, a benzyl group, and an allyl group.
优选地,其中一种为3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其结构通式为:Preferably, one of them is 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c), and its general structural formula is:
其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种。The R group is selected from any one of -H, alkyl, alkenyl, alkynyl and aryl.
优选地,其中一种为3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其结构通式为:Preferably, one of them is 3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), and its general structural formula is:
其中,R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种。Wherein, the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl.
优选地,其中一种为3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其结构通式为:Preferably, one of them is 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e), and its general structural formula is:
其中,R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种。Wherein, the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester and aldehyde.
优选地,其中一种为3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其结构通式为:Preferably, one of them is 3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), and its general structural formula is:
其中,R基选自烷基、烯基、芳基、磺酰基中的任一种。The R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.
优选地,所述功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:Preferably, the method for preparing the functionalized D-glucal compound is characterized in that the preparation route of the functionalized D-glucal compound is:
其中,3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖(VII-a),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与取代烯丙基羧酸a缩合,羧酸a的结构式为其中R基选自-H、烷基、烯基、炔基、芳基中的任一种;Among them, 3-O-acryloyl-4,6-O-acetone-D-glucal (VII-a) is prepared by condensing 4,6-O-acetone-D-glucal VI with substituted allyl carboxylic acid a, wherein the structural formula of carboxylic acid a is Wherein the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl;
3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔酯b加成,丙炔酯b结构式为其中,R基选自烷基、苄基、烯丙基中的任一种。3-O-propenyl ester-4,6-O-acetone formate-D-glucal (VII-b), the preparation method of which is to use 4,6-O-acetone formate-D-glucal VI to add propargyl ester b, the structural formula of propargyl ester b is The R group is selected from any one of an alkyl group, a benzyl group, and an allyl group.
优选地,所述的功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:Preferably, the method for preparing the functionalized D-glucal compound is characterized in that the preparation route of the functionalized D-glucal compound is:
其中,3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔卤代物c亲核取代,丙炔卤代物c结构式为其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种,X选自Cl、Br、OMs中的任一种;Among them, 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c) is prepared by using 4,6-O-acetone-D-glucal VI and propyne halide c for nucleophilic substitution, and the structural formula of propyne halide c is Wherein, the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl, and X is selected from any one of Cl, Br, and OMs;
3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与吡啶卤代物d芳香亲核取代,吡啶卤代物d结构式为其中R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种,X基选自F、Cl、Br、OMs中的任一种。3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), the preparation method of which is to use 4,6-O-acetone-D-glucal VI and pyridine halide d for aromatic nucleophilic substitution, the pyridine halide d has the structural formula The R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl, and the X group is selected from any one of F, Cl, Br, and OMs.
优选地,所述的功能化D-葡萄烯糖化合物的制备方法,其特征在于,所述功能化D-葡萄烯糖化合物的制备路线为:Preferably, the method for preparing the functionalized D-glucal compound is characterized in that the preparation route of the functionalized D-glucal compound is:
其中,3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与苄基卤代物e亲核取代,苄基卤代物e结构式为其中R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种,X基选自Cl、Br、OMs中的任一种;Among them, 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e) is prepared by using 4,6-O-acetone-D-glucal VI and benzyl halide e for nucleophilic substitution, and the benzyl halide e has the structural formula Wherein the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester, and aldehyde, and the X group is selected from any one of Cl, Br, and OMs;
3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其制备方法为使用3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c1)与叠氮化物f进行[3+2]环加成反应获得,叠氮化物f结构式为RN3,其中R基选自烷基、烯基、芳基、磺酰基中的任一种。3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), which is prepared by a [3+2] cycloaddition reaction of 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c 1 ) and azide f, wherein the structural formula of azide f is RN 3 , wherein the R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.
本发明相对于现有技术的有益效果是:首次在4,6-O-丙酮叉-D-葡萄烯糖的3-O位安装了六种官能团,得到六类新的烯糖化合物。这些化合物不仅本身具有学术和潜在的药物化学价值,它们还可以方便地进一步转化为其它新物质,特别地可发生分子内的环化或重排反应等。The beneficial effects of the present invention over the prior art are: for the first time, six functional groups are installed at the 3-O position of 4,6-O-acetone-D-glucal to obtain six new glucal compounds. These compounds not only have academic and potential medicinal chemical value, but can also be conveniently further converted into other new substances, especially intramolecular cyclization or rearrangement reactions can occur.
具体实施方式DETAILED DESCRIPTION
一种功能化D-葡萄烯糖化合物,具有通式结构VII,根据其功能取代基FG的种类分别用如下结构式VII-a、VII-b、VII-c、VII-d、VII-e和VII-f表示:A functionalized D-glucal compound has a general structure VII, and is represented by the following structural formulas VII-a, VII-b, VII-c, VII-d, VII-e and VII-f respectively according to the type of its functional substituent FG:
本发明提供了所述功能化D-葡萄烯糖化合物的制备方法,具体制备路线为:The present invention provides a method for preparing the functionalized D-glucal compound, and the specific preparation route is:
具体地,这六种功能化D-葡萄烯糖化合物分别为:Specifically, the six functionalized D-glucal compounds are:
第一种,3-O-丙烯酰基-4,6-O-丙酮叉-D-葡萄烯糖VII-a的制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与取代烯丙基羧酸a缩合,羧酸a的结构式为其中R基选自-H、烷基、烯基、炔基、芳基中的任一种;The first method is to prepare 3-O-acryloyl-4,6-O-acetone-D-glucal VII-a by condensing 4,6-O-acetone-D-glucal VI with substituted allyl carboxylic acid a, wherein the structural formula of carboxylic acid a is Wherein the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl;
第二种,3-O-丙烯基酯-4,6-O-丙酮叉-D-葡萄烯糖(VII-b),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔酯b加成,丙炔酯b结构式为其中,R基选自烷基、苄基、烯丙基中的任一种;The second type, 3-O-propenyl ester-4,6-O-acetone foridene-D-glucal (VII-b), is prepared by adding 4,6-O-acetone foridene-D-glucal VI to propargyl ester b, the structural formula of which is Wherein, the R group is selected from any one of an alkyl group, a benzyl group, and an allyl group;
第三种,3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与丙炔卤代物c亲核取代,丙炔卤代物c结构式为其中,R基选自-H、烷基、烯基、炔基、芳基中的任一种,X选自Cl、Br、OMs中的任一种。The third type, 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c), is prepared by using 4,6-O-acetone-D-glucal VI and propyne halide c for nucleophilic substitution. The structural formula of propyne halide c is Wherein, the R group is selected from any one of -H, alkyl, alkenyl, alkynyl, and aryl, and X is selected from any one of Cl, Br, and OMs.
第四种,3-O-吡啶基-4,6-O-丙酮叉-D-葡萄烯糖(VII-d),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与吡啶卤代物d芳香亲核取代,吡啶卤代物d结构式为其中R基选自-H、卤素、烷基、烯基、炔基、芳基中的任一种,X基选自F、Cl、Br、OMs中的任一种;The fourth type, 3-O-pyridyl-4,6-O-acetone-D-glucal (VII-d), is prepared by using 4,6-O-acetone-D-glucal VI to perform aromatic nucleophilic substitution with a pyridine halide d. The structural formula of the pyridine halide d is Wherein the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, and aryl, and the X group is selected from any one of F, Cl, Br, and OMs;
第五种,3-O-苄基-4,6-O-丙酮叉-D-葡萄烯糖(VII-e),其制备方法为使用4,6-O-丙酮叉-D-葡萄烯糖VI与苄基卤代物e亲核取代,苄基卤代物e结构式为其中R基选自-H、卤素、烷基、烯基、炔基、芳基、硝基、酯基、醛基中的任一种,X基选自Cl、Br、OMs中的任一种;The fifth type, 3-O-benzyl-4,6-O-acetone-D-glucal (VII-e), is prepared by using 4,6-O-acetone-D-glucal VI and benzyl halide e for nucleophilic substitution. The benzyl halide e has the structural formula Wherein the R group is selected from any one of -H, halogen, alkyl, alkenyl, alkynyl, aryl, nitro, ester, and aldehyde, and the X group is selected from any one of Cl, Br, and OMs;
第六种,3-O-亚甲基三氮唑-4,6-O-丙酮叉-D-葡萄烯糖(VII-f),其制备方法为使用3-O-丙炔基-4,6-O-丙酮叉-D-葡萄烯糖(VII-c1)与叠氮化物f进行[3+2]环加成反应获得,叠氮化物f结构式为RN3,其中R基选自烷基、烯基、芳基、磺酰基中的任一种。The sixth type, 3-O-methylenetriazole-4,6-O-acetone-D-glucal (VII-f), is prepared by a [3+2] cycloaddition reaction of 3-O-propynyl-4,6-O-acetone-D-glucal (VII-c 1 ) and azide f. The structural formula of azide f is RN 3 , wherein the R group is selected from any one of an alkyl group, an alkenyl group, an aryl group, and a sulfonyl group.
实施例1Example 1
将VI(540mg,3.01mmol)溶解在15mL无水二氯甲烷(DCM)中,在氮气氛围下向反应瓶中加入化合物a1(681.0mg,3.91mmol)4-二甲氨基吡啶(DMAP)(367.4mg,3.01mmol),然后将反应冷却至0℃,加入1,3-二环己基碳二亚胺(DCC)(806.69mg,3.91mmol),最后将反应逐渐升温至室温反应过夜。用TLC检测反应结束后,加水淬灭反应,然后用二氯甲烷(3x 10mL)萃取,然后用饱和食盐水15mL萃取,收集有机相用无水硫酸钠干燥,最后减压浓缩,快速通过柱层析得到VII-a1(566.5mg),白色固体,产率为55%。1H NMR(400MHz,CDCl3)δ7.54–7.40(m,3H),7.41–7.27(m,3H),6.88(d,J=8.7Hz,2H),6.37(dd,J=6.1,1.4Hz,1H),6.01(d,J=15.2Hz,1H),5.48(dt,J=7.8,1.7Hz,1H),4.81(dd,J=6.1,2.0Hz,1H),4.12(dd,J=9.8,7.9Hz,1H),3.98(t,J=4.5Hz,1H),3.92–3.79(m,2H),1.55(s,3H),1.43(s,3H).VI (540 mg, 3.01 mmol) was dissolved in 15 mL of anhydrous dichloromethane (DCM), and compound a 1 (681.0 mg, 3.91 mmol) and 4-dimethylaminopyridine (DMAP) (367.4 mg, 3.01 mmol) were added to the reaction bottle under a nitrogen atmosphere, and then the reaction was cooled to 0°C, 1,3-dicyclohexylcarbodiimide (DCC) (806.69 mg, 3.91 mmol) was added, and finally the reaction was gradually heated to room temperature and reacted overnight. After the reaction was detected by TLC, water was added to quench the reaction, and then extracted with dichloromethane (3x 10 mL), and then extracted with 15 mL of saturated brine, the organic phase was collected and dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure, and quickly passed through column chromatography to obtain VII-a 1 (566.5 mg) as a white solid with a yield of 55%. 1 H NMR (400MHz, CDCl 3 ) δ7.54–7.40(m,3H),7.41–7.27(m,3H),6.88(d,J=8.7Hz,2H),6.37(dd,J=6.1,1.4Hz,1H),6.01(d,J=15.2Hz,1H),5.48(dt,J=7.8,1 .7Hz,1H),4.81(dd,J=6.1,2.0Hz,1H),4.12(dd,J=9.8,7.9Hz,1H),3.98(t,J=4.5Hz,1H),3.92–3.79(m,2H),1.55(s,3H),1.43(s,3H).
实施例2Example 2
将VI(626.4mg,3.36mmol)溶解在15mL无水四氢呋喃中,然后在氮气保护下加入1,4-二氮杂二环[2.2.2]辛烷(DABCO),接着缓慢滴加b1,室温反应5h。反应结束后,混合物中加入20mL氢氧化钠水溶液(1M),乙醚(3x 15mL)萃取,收集有机相,用无水硫酸钠干燥,最后减压浓缩,通过硅胶柱纯化,最后得到VII-b1(660mg),白色固体,产率为79.9%。1H NMR(400MHz,CDCl3)δ7.60(d,J=12.4Hz,1H),6.39(dd,J=6.2,1.2Hz,1H),5.33(d,J=12.4Hz,1H),4.76(dd,J=6.2,1.9Hz,1H),4.60(dt,J=7.4,1.7Hz,1H),4.09–3.91(m,2H),3.89–3.74(m,2H),3.69(s,3H),1.51(s,3H),1.43(s,3H).VI (626.4 mg, 3.36 mmol) was dissolved in 15 mL of anhydrous tetrahydrofuran, and then 1,4-diazabicyclo[2.2.2]octane (DABCO) was added under nitrogen protection, followed by slow dropwise addition of b 1 , and the mixture was reacted at room temperature for 5 h. After the reaction, 20 mL of sodium hydroxide aqueous solution (1 M) was added to the mixture, and the mixture was extracted with ether (3 x 15 mL), the organic phase was collected, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure and purified by silica gel column to obtain VII-b 1 (660 mg) as a white solid with a yield of 79.9%. 1 H NMR (400MHz, CDCl 3 ) δ7.60 (d, J=12.4Hz, 1H), 6.39 (dd, J=6.2, 1.2Hz, 1H), 5.33 (d, J=12.4Hz, 1H), 4.76 (dd, J=6.2, 1.9Hz, 1H), 4.60 (dt, J=7.4, 1.7Hz, 1H) ,4.09–3.91(m,2H),3.89–3.74(m,2H),3.69(s,3H),1.51(s,3H),1.43(s,3H).
实施例3Example 3
将VI(500mg,2.69mmol)溶解在10mL无水四氢呋喃中,然后将反应瓶冷却至0℃,在氮气保护下加入氢化钠(161.1mg,4.03mmol,60%),将混合物在0℃反应30分钟,随后将c1(0.28mL,3.22mmol)缓慢加入反应体系中,室温反应2h。反应结束后,向体系中加入冰水淬灭反应,然后用乙酸乙酯(3x 15mL)萃取,收集有机相,用饱和食盐水(20mL)干燥,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物,最后得到VII-c1(306mg),无色液体,产率为50%。1H NMR(400MHz,CDCl3)δ6.30(d,J=6.2Hz,1H),4.87–4.65(m,1H),4.42–4.16(m,3H),4.03–3.86(m,2H),3.81(t,J=10.5Hz,1H),3.71(td,J=10.3,5.6Hz,1H),2.43(s,1H),1.51(s,3H),1.40(s,3H).VI (500 mg, 2.69 mmol) was dissolved in 10 mL of anhydrous tetrahydrofuran, and then the reaction flask was cooled to 0°C. Sodium hydride (161.1 mg, 4.03 mmol, 60%) was added under nitrogen protection, and the mixture was reacted at 0°C for 30 minutes, and then c 1 (0.28 mL, 3.22 mmol) was slowly added to the reaction system, and the reaction was carried out at room temperature for 2 hours. After the reaction was completed, ice water was added to the system to quench the reaction, and then ethyl acetate (3 x 15 mL) was used for extraction, and the organic phase was collected and dried with saturated brine (20 mL), and then the organic phase was dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product was quickly purified by silica gel column to obtain VII-c 1 (306 mg), a colorless liquid, with a yield of 50%. 1 H NMR (400MHz, CDCl 3 ) δ6.30(d,J=6.2Hz,1H),4.87–4.65(m,1H),4.42–4.16(m,3H),4.03–3.86(m,2H),3.81(t,J=10.5Hz,1H),3.71(td,J=10.3,5.6Hz, 1H),2.43(s,1H),1.51(s,3H),1.40(s,3H).
实施例4Example 4
将VI(300mg,1.61mmol)溶解在20mL无水四氢呋喃中,抽空换氮三次,然后冷却至0℃,氮气保护下加入氢化钠(161.1mg,4.03mmol,60%),然后0℃下搅拌30分钟,接着向混合物中加入d1,室温反应2小时。反应结束后,向混合物中加入20mL水淬灭反应,然后用然后用乙酸乙酯(3x 15mL)萃取水相,收集有机相,用饱和食盐水(20mL)洗涤,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物,最后得到化合物VII-d1(376.7mg),无色液体,产率为75.8%。1H NMR(400MHz,CDCl3)δ9.16–8.99(m,1H),8.36(dd,J=9.1,2.8Hz,1H),7.04–6.63(m,1H),6.40(dd,J=6.1,1.4Hz,1H),5.91–5.64(m,1H),4.89(dd,J=6.1,2.0Hz,1H),4.30–4.17(m,1H),3.95(ddd,J=8.4,6.6,3.5Hz,3H),1.57(s,3H),1.41(s,3H).VI (300 mg, 1.61 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran, evacuated and replaced with nitrogen three times, then cooled to 0°C, sodium hydride (161.1 mg, 4.03 mmol, 60%) was added under nitrogen protection, and then stirred at 0°C for 30 minutes, and then d 1 was added to the mixture, and reacted at room temperature for 2 hours. After the reaction was completed, 20 mL of water was added to the mixture to quench the reaction, and then the aqueous phase was extracted with ethyl acetate (3x 15 mL), the organic phase was collected, washed with saturated brine (20 mL), and then the organic phase was dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product was quickly purified by silica gel column to obtain compound VII-d 1 (376.7 mg), a colorless liquid, with a yield of 75.8%. 1 H NMR (400MHz, CDCl 3 ) δ9.16–8.99(m,1H),8.36(dd,J=9.1,2.8Hz,1H),7.04–6.63(m,1H),6.40(dd,J=6.1,1.4Hz,1H),5.91–5.64(m,1H),4.89(dd,J=6.1 ,2.0Hz,1H),4.30–4.17(m,1H),3.95(ddd,J=8.4,6.6,3.5Hz,3H),1.57(s,3H),1.41(s,3H).
实施例5Example 5
将VI(200mg,1.07mmol)溶解在15mL无水四氢呋喃中,抽空换氮三次,然后冷却至0℃,氮气保护下加入氢化钠(85.92mg,2.15mmol,60%),然后0℃下搅拌30分钟,接着向混合物中加入e1,室温反应2小时。反应结束后,向混合物中加入20mL水淬灭反应,然后用然后用乙酸乙酯(3x 15mL)萃取水相,收集有机相,用饱和食盐水(20mL)洗涤,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物,最后得到化合物VII-e1(233mg),无色液体,产率为61%。1H NMR(400MHz,CDCl3)δ7.53(ddd,J=4.9,3.1,1.0Hz,2H),7.31(td,J=7.5,1.1Hz,1H),7.15(dd,J=7.7,1.6Hz,1H),6.34(dd,J=6.1,1.6Hz,1H),4.88–4.78(m,2H),4.75–4.68(m,1H),4.25(dt,J=7.3,1.8Hz,1H),4.05(dd,J=10.3,7.3Hz,1H),3.96(dd,J=10.8,5.6Hz,1H),3.85(t,J=10.5Hz,1H),3.76(dd,J=10.3,5.6Hz,1H),1.49(s,3H),1.44(s,3H).VI (200 mg, 1.07 mmol) was dissolved in 15 mL of anhydrous tetrahydrofuran, evacuated and replaced with nitrogen three times, then cooled to 0°C, sodium hydride (85.92 mg, 2.15 mmol, 60%) was added under nitrogen protection, and then stirred at 0°C for 30 minutes, and then e 1 was added to the mixture, and reacted at room temperature for 2 hours. After the reaction was completed, 20 mL of water was added to the mixture to quench the reaction, and then the aqueous phase was extracted with ethyl acetate (3x 15 mL), the organic phase was collected, washed with saturated brine (20 mL), and then the organic phase was dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product was quickly purified by silica gel column to obtain compound VII-e 1 (233 mg), a colorless liquid with a yield of 61%. 1 H NMR (400 MHz, CDCl 3 )δ7.53(ddd,J=4.9,3.1,1.0Hz,2H),7.31(td,J=7.5,1.1Hz,1H),7.15(dd,J=7.7,1.6Hz,1H),6.34(dd,J=6.1,1.6Hz,1H),4.88–4.78(m,2H),4.75–4.68( m,1H),4.2 5(dt,J=7.3,1.8Hz,1H),4.05(dd,J=10.3,7.3Hz,1H),3.96(dd,J=10.8,5.6Hz,1H),3.85(t,J=10.5Hz,1H),3.76(dd,J=10.3,5.6Hz,1H),1.49(s,3H),1.4 4(s,3H).
实施例6Example 6
将TcCu(51.47mg,0.27mmol)溶解在5mL无水甲苯中,然后进行氮气保护,接着将化合物VII-c1(500mg,2.69mmol)溶解在15mL甲苯溶液中,将f1(582.5mg,2.95mmol)溶解在15mL甲苯溶液中,依次将二者加入到噻吩-2-甲酸亚铜(TcCu)中,室温反应。反应结束后,向反应体系中加入20mL水,用乙酸乙酯(3x 20mL)萃取,收集有机相,用饱和食盐水(20mL)干燥,然后有机相用无水硫酸钠干燥,最后减压浓缩,快速通过硅胶柱纯化产物VII-f1(802.3mg),产率为71%。1H NMR(400MHz,CDCl3)δ8.16(s,1H),8.16(s,1H),7.99(d,J=8.4Hz,2H),7.38(d,J=8.1Hz,2H),6.33(dd,J=6.1,1.4Hz,1H),4.98–4.64(m,3H),4.32–4.12(m,1H),4.06–3.63(m,5H),2.45(s,3H),2.17(s,1H),1.48(d,J=13.9Hz,3H),1.45(d,J=6.3Hz,3H).TcCu (51.47 mg, 0.27 mmol) was dissolved in 5 mL of anhydrous toluene, and then nitrogen protection was performed. Then, compound VII-c 1 (500 mg, 2.69 mmol) was dissolved in 15 mL of toluene solution, and compound f 1 (582.5 mg, 2.95 mmol) was dissolved in 15 mL of toluene solution, and the two were added to thiophene-2-carboxylic acid cuprous acid (TcCu) in sequence, and reacted at room temperature. After the reaction was completed, 20 mL of water was added to the reaction system, and extracted with ethyl acetate (3 x 20 mL), and the organic phase was collected and dried with saturated brine (20 mL), and then the organic phase was dried with anhydrous sodium sulfate, and finally concentrated under reduced pressure, and the product VII-f 1 (802.3 mg) was quickly purified by silica gel column, and the yield was 71%. 1 H NMR (400MHz, CDCl 3 ) δ8.16(s,1H),8.16(s,1H),7.99(d,J=8.4Hz,2H),7.38(d,J=8.1Hz,2H),6.33(dd,J=6.1,1.4Hz,1H),4.98–4.64(m,3H),4.32–4.1 2(m,1H),4.06–3.63(m,5H),2.45(s,3H),2.17(s,1H),1.48(d,J=13.9Hz,3H),1.45(d,J=6.3Hz,3H).
本发明公开了若干种新型葡萄烯糖分子及其制备方法。具体公开了六种3-位羟基上官能化的葡萄烯糖化合物及其合成方法,该类化合物使用关键中间体4,6-O-丙酮叉-D-葡萄烯糖,采用不同的反应技术,在其3-位的羟基上安装六种不同的官能团,得到相应的功能化的六种葡萄烯糖衍生物。这些新型烯糖在合成化学合药物化学领域具有潜在的应用价值。The present invention discloses several novel glucal molecules and preparation methods thereof. Specifically, six glucal compounds functionalized on the 3-hydroxyl group and synthesis methods thereof are disclosed. The compounds use the key intermediate 4,6-O-acetone-D-glucal and adopt different reaction technologies to install six different functional groups on the 3-hydroxyl group thereof to obtain six functionalized glucal derivatives. These novel glucal molecules have potential application value in the fields of synthetic chemistry and medicinal chemistry.
以上述依据本发明的较佳实施例为启示,通过上述的说明内容,相关工作人员完全可以在不偏离本项发明技术思想的范围内,进行多样的变更以及修改。本项发明的技术性范围并不局限于说明书上的内容,必须要根据权利要求范围来确定其技术性范围。Based on the above preferred embodiments of the present invention, the relevant staff can make various changes and modifications without departing from the technical concept of the present invention through the above description. The technical scope of the present invention is not limited to the content in the specification, and its technical scope must be determined according to the scope of the claims.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310246203.8A CN116199698A (en) | 2023-03-15 | 2023-03-15 | Functionalized D-glucal compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310246203.8A CN116199698A (en) | 2023-03-15 | 2023-03-15 | Functionalized D-glucal compound and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116199698A true CN116199698A (en) | 2023-06-02 |
Family
ID=86514637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310246203.8A Pending CN116199698A (en) | 2023-03-15 | 2023-03-15 | Functionalized D-glucal compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116199698A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101245057A (en) * | 2007-02-13 | 2008-08-20 | 中国科学院成都生物研究所 | A kind of preparation method of glucal |
| CN102397270A (en) * | 2010-09-17 | 2012-04-04 | 苏州天人合生物技术有限公司 | Application of glucal and glucal derivative in preparation of medicines |
-
2023
- 2023-03-15 CN CN202310246203.8A patent/CN116199698A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101245057A (en) * | 2007-02-13 | 2008-08-20 | 中国科学院成都生物研究所 | A kind of preparation method of glucal |
| CN102397270A (en) * | 2010-09-17 | 2012-04-04 | 苏州天人合生物技术有限公司 | Application of glucal and glucal derivative in preparation of medicines |
Non-Patent Citations (5)
| Title |
|---|
| ACS: "RN:158053-94-2化合物", 《STN REGISTRY数据库》, 30 September 1994 (1994-09-30), pages 158053 - 94 * |
| ACS: "RN:58871-07-1化合物", 《STN REGISTRY数据库》, 16 November 1984 (1984-11-16), pages 58871 - 07 * |
| JOSE MARCO-CONTELLES: "Asymmetric Pauson-Khand Reaction. Cobalt-Mediated Cycloisomerization of 1, 6-Enynes in Carbohydrate Templates: Synthesis of Bis-Heteroannulated Pyranosides", 《J.ORG.CHEM.》, vol. 61, 31 December 1996 (1996-12-31), pages 7667 * |
| MARKUS LEIBELING等: "Domino access to highly substituted chromans and isochromans from carbohydrates", 《NATURE CHEMICAL BIOLOGY》, vol. 6, 24 January 2010 (2010-01-24), pages 22 * |
| PETER H. SEEBERGER等: "Selective formation of C-2 azidodeoxy-D-glucose derivatives from D-glucal precursors using the azidonitration reaction", 《CARBOHYDRATE RESEARCH》, vol. 328, 31 December 2000 (2000-12-31), pages 63 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110330500B (en) | Stereoselective synthesis method of 6 beta-hydroxy-7, 8-dihydro-morphine derivative | |
| CN111233795A (en) | Preparation method and application of chiral gamma-butyrolactone compound and derivative thereof | |
| CN108558692B (en) | A kind of preparation method of amide compound | |
| CN106496183A (en) | Macrolide derivatives of caffeic acid ester connection and preparation method thereof | |
| CN114163436A (en) | Diarylmethane derivative containing indolizine and preparation method and application thereof | |
| CN114539252A (en) | 2, 3-dihydroquinoline-4-ketone bioactive skeleton and synthesis method and application thereof | |
| CN105348341B (en) | A kind of method for preparing rope Citropten | |
| CN116199698A (en) | Functionalized D-glucal compound and preparation method thereof | |
| CN103319497B (en) | Preparation method of natural product Hirtellanine B and its derivatives and application in preparation of drugs for treating tumors | |
| CN112979529A (en) | Aromatic amine indole naphthoquinone derivative and preparation method thereof | |
| CN110343117B (en) | Process for the preparation of artemisinin derivatives | |
| CN118598812A (en) | Synthesis method of key intermediate of huperzine A | |
| CN111187279A (en) | Blue calyxine-biotin-based small molecule probe and its preparation method and application | |
| CN115353522A (en) | Regioselective synthesis and anti-tumor application of icaritin-norcantharidin conjugate | |
| Kumar et al. | A Novel One-pot Synthesis of 2 H-4-Chlorochromenes via the Vilsmeier Reaction of 2′-Hydroxychalcones | |
| CN103848874B (en) | The method of the tetra-acetylated-L-gulose of synthesis 1,3,4,6- | |
| CN108329300B (en) | Nitrobenzo [ d ] aza-quinazoline compound and preparation method and application thereof | |
| CN115536571A (en) | Preparation method of indole derivative | |
| CN114605421A (en) | Spiro-2, 3-dihydroquinoline-4-ketone-3, 4-dihydrocoumarin bioactive skeleton and synthesis method and application thereof | |
| CN114891005B (en) | Preparation process of Wupalision p-toluenesulfonate | |
| CN114805168B (en) | Pyrrolinones and synthesis method thereof | |
| CN116283761B (en) | A 3-alkenyl ketone substituted quinoline-2-one and a green synthesis method thereof | |
| CN119060059B (en) | Preparation process of Li Texi tenib tosylate | |
| CN115925702B (en) | A purification method of imidazo[4,5-C]pyridine derivatives and imidazo[4,5-C]pyridine derivatives | |
| CN113292573B (en) | Indolizine chromogen ketone compound with anti-tumor activity and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |